Stimulated enrichment of Clostridium difficile specific IgA in mature cow's milk

Hematological Changes in Sika Doe and Suckling Fawn Fed with Spent Mushroom Substrate of Pleurotus ostreatus

Sika deer velvet antler is the most important animal nutraceutic in traditional Chinese medicine. Reducing the breeding cost of sika deer by looking for a low-cost diet is the main research direction at present. The purpose of this experiment was to find an alternative diet for sika deer and reduce the cost of the diet by using spent mushroom substrate (SMS) as a concentrate supplement. The apparent digestibility for sika doe and the hematological changes of sika doe and suckling fawn were measured by replacing 10% of the concentrate supplement with SMS of Pleurotus ostreatus (SMS-MP). Compared with the control group, the digestibility of dry matter (DM), total protein (TP), globulin (GLO), and cholesterol (CHOL) of sika doe were significantly decreased (p < 0.05), and glucose (GLU), alanine (Ala), phenylalanine (Phe), and proline (Pro) of sika doe were significantly increased (p < 0.05) after the replacement of SMS-MP. Compared with the control group, the serum GLU of suckling fawn was significantly decreased (p < 0.05) and the phosphatase (ALP) was significantly increased after the replacement of SMS-MP (p < 0.05). There were no significant differences in the immune globulin and amino acid of suckling fawns between the two groups (p > 0.05). The present findings confirm the applicability of SMS-MP as a sika doe concentrate supplement. At the same time, using SMS, a waste resource, can not only reduce the breeding cost of sika doe, but also make full use of SMS to reduce environmental pollution.

Role of IgA in the early-life establishment of the gut microbiota and immunity: Implications for constructing a healthy start

Colonization and maturation of the gut microbiota (GM) during early life is a landmark event that fundamentally influences the (early) immunity and later-life health of various mammals. This is a delicate, systematic process that is biologically actively regulated by infants and their mothers, where (secretory) IgA, an important regulator of microbes found in breast milk and generated actively by infants, may play a key role. By binding to microbes, IgA can inhibit or enhance their colonization, influence their gene expression, and regulate immune responses. IgA dysfunction during early life is associated with disrupted GM maturation and various microbe-related diseases, such as necrotizing enterocolitis and diarrhea, which can also have a lasting effect on GM and host health. This review discusses the process of early GM maturation and its interaction with immunity and the role of IgA (focusing on milk secretory IgA) in regulating this process. The possible application of this knowledge in promoting normal GM maturation processes and immune education has also been highlighted.

Immune cell counts and signaling in body fluids of cows vaccinated against Clostridium difficile

BACKGROUND

New treatment options are needed to prevent relapses following failed antibiotic therapies of Clostridium difficile infections (CDI) in humans. The concomitant therapy with an anti-C. difficile IgA containing whey protein concentrate can support the sustainable recovery of CDI patients. For 31 weeks, nine dairy cows were continuously vaccinated with several anti-C. difficile vaccines by certain routes of administration to produce anti-C. difficile IgA enriched milk. The study aimed at finding decisive differences between low responder (LR) and high responder (HR) cows (> 8.0 µg ml-1 total milk C. difficile specific IgA) concerning their immune response to vaccination on cellular and molecular biological levels.

RESULTS

The results of total and differential cell counting (DCC) in blood and milk and the outcomes of the gene expression analysis of selected immune factors were assessed relating to the usage of two vaccine batches for injection (MucoCD-I batch A and B), marking two immunization (IM) periods, and compared to a control group (Ctr). The MucoCD-I batch A caused short-term leukopenia followed by leukocytosis in the blood of LR and HR. The total somatic cell counts in milk were not altered by the treatment. The DCC revealed that the leukocytes of the treated groups were partly impaired by the treatment. The gene expression analysis exposed cumulative and sustainable differences (p < 0.05) between LR and HR for the genes encoding for lactoferrin, CXCL8, IL1β, IL2, IL6, IL12β, IFNγ, CD4 and CD163. The regulation of the epithelial IgA cell receptor PIGR was not impaired by the IM. In contrast to the vaccination with MucoCD-I batch A, the second IM period with MucoCD-I batch B resulted in mitigation and synchronization of the treated groups' immune responses.

CONCLUSIONS

The inversely regulated cytokines in the blood and milk cells of the treated groups led to a variously directed, local T cell response resulting in their different production intensities of C. difficile specific IgA in milk.

Application of Antibody-Mediated Therapy for Treatment and Prevention of Clostridium difficile Infection

Clostridium difficile causes antibiotic- and healthcare-associated diarrhea, which is characterized by a high mortality rate (5–15%) and high recurrence rate of 20% or more. Therapeutic alternatives to antibiotics are urgently needed to improve the overall cure rate. Among these, therapeutic antibodies have shown promising results in clinical studies. Herein, the authors review current monoclonal and polyclonal anti- C. difficile antibodies that have entered the clinical development stage, either for systemic administration or by the oral route. The antibodies can be applied as monotherapy or in combination with standard-of-care to treat an infection with C. difficile or to protect from a recurrence. Bezlotoxumab is the first antibody for secondary prevention of recurrence of C. difficile infection approved by the regulatory agencies in US and Europe. The human monoclonal antibody is administered systemically to patients receiving oral standard-of–care antibiotics. Other antibodies are currently in the clinical pipeline, and some are intended for oral use. They show a good safety profile, high efficacy and low production costs, and can be considered promising therapies of the future. The most promising orally administered drug candidate is a bovine antibody from hyperimmune colostral milk, which is in an advanced clinical development stage. Which antibody will enter the market is dependent on its bioavailability at the site of infection as well as its activity against C. difficile toxins, protection against colonization and possible action on spore formation. The antibody must demonstrate a clear benefit in comparison with other available treatment options to be considered for use by clinicians.